Insights
From phenotype to genotype: closing the diagnostic odyssey
Patients with rare diseases often wait years for answers. Connecting structured phenotyping with genomic testing is one of the most direct ways to shorten that journey.
The diagnostic odyssey is familiar to every rare disease team: repeated visits, inconclusive tests, and families carrying uncertainty for years. Much of the delay is not sequencing capacity—it is the gap between what clinicians observe and what labs receive.
Structured phenotyping tools, including HPO-based capture, help teams express clinical findings in forms that travel cleanly into genomic workflows. That alignment improves test selection and focuses interpretation on biologically plausible variants.
When phenotype and genotype data stay linked in one case, reanalysis becomes practical. New gene-disease associations and updated classification criteria can be applied without rebuilding the chart from scratch.
Families benefit when progress is visible. A shared case timeline—symptoms captured, tests ordered, variants reviewed, reports issued—reduces the sense that care is stalled in invisible back offices.
Closing the odyssey will require institutional commitment, but the technical path is increasingly clear: unify phenotype capture, genomic analysis, and multidisciplinary review in one longitudinal record built for rare disease complexity.